There is insufficient understanding of phage treatment of human infections ?

Mmmm !

The obvious thing to do

Link

To get going at long last!

Here

 pdf

  Et chapeau bas à Georgia!

Silk route to the acceptance and re-implementation of bacteriophage therapy

Link

My opinion:
phage preparation by genetic engineering  is a time-consuming job and from realistic point of view it clashes with the rapidity  of an appropriate antibacterial therapy (the patient could be in a danger situation and the action time could be short).

 

If in a country the constitution and the updating of a Bank for circulating natural lytic phages used in phage therapy  is hard and expensive, the constitution and the updating of a  Bank for genetic engineering phages used in phage therapy is very hard and very expensive.
The use of natural lytic phages may reduce  these aspects.

Phage therapy is not for all bacterial infections

If we consider the  work experience  hoarded in the Ex-USSR countries about phage therapy such as a reference model and a good starting point then it is important does not forget that Phage therapy application can not diseregard  from the following points:

1-Phage therapy is not for all bacterial infections.
2-It is necessary to make a priority list of  all bacterial infections where Phage therapy could be effective.
In general  terms Phage Therapy Efficacy follows a decreasing gradient in the recovery chances.
Both recovery results and Phage presence are linked to the anatomical Site where a bacterial Infection is localized and active.
This decreasing Efficacy Gradient starts from the infective processes on the external surface of the Body to the infective processes on the intestinal mucosa , urinary tract and in the end, to the infective processes reached by bloodstream only.
When the infection site is localized on the skin we may have the best recovery chance by Phage therapy .




3-Phage therapy must be a timely remedy and easy . It is important does not lose time. For this raison it is necessary to have a national data bank on circulating bacteria and for sending to the hospital lab corresponding phages ready for use.

4-Phage therapy requires only Phage cocktails.  Phage cocktail must be well characterized and its effect monitored in the time.

WHO: Buruli ulcer (Mycobacterium ulcerans infection) Fact sheet updated February 2016

Link

La phagothérapie, une médecine ancestrale pour lutter....

 19 feb 2016
TF1
Video Link

Production of Phages for Clinical Trials

Link

Link

PHAGE THERAPY 2016, Paris

Link

PhagoBurn Booklet

Link

BACTERIOPHAGE 2016,London

 

Link

Link

Phage therapy new book

“Phage Therapy 2.0”

Link

Verbeken G. (2015) "Towards an Adequate Regulatory Framework for Bacteriophage Therapy"

  
 From  Phagoburn: published doctoral Thesis,
University KU LEuven and Royal Military Academy, Brussel, Belgium

 Verbeken G. (2015) "Towards an Adequate Regulatory Framework for Bacteriophage Therapy"

Encapsulated bacteriophages for enhanced oral phage therapy

Read more at: http://phys.org/news/2015-10-encapsulated-bacteriophages-oral-phage-therapy.html#jCp

Link

This research found that nanoencapsulation confers to bacteriophages a greater resistance to the effects of the stomach low pH while also increasing their residence time in the intestinal tract.

News from PhagoBurn

old post

• Participation to the ICAAC-ICC 2015 Meeting - September 18^th, 2015

Gregory Resch (CHUV) took part in the ICAAC-ICC Meeting which was held in San Diego (CA, United States). He gave a talk entitled "Phage-based Therapies", with a specific focus on Phagoburn.

here

• Participation to the 16^th Congress of the European Burn Association - September 18^th, 2015

Jean-Paul Pirnay (Queen Astrid) gave a talk during the annual congress of the EBA, which took place in Hannover, Germany in September 2015. He presented PhagoBurn and specifically the launching of the clinical study.

here 

• Participation to Evergreen Conference - August 2-7^th, 2015

Jérôme Gabard (Pherecydes) took part in the 21st Biennial Evergreen International Phage Meeting which was held in Evergreen (WA, United States). During this event, he presented the progress of Phagoburn project since the previous Meeting.

here

• Participation to NIH Conference - July 20^th, 2015

Patrick Jault (HIA Percy) gave a talk during a NIH Meeting which took place in Rockville (United States), in July. This talk specifically presented PhagoBurn and the launching of the clinical trial.

here 

• Participation to Bacteriophages 2015 - January 27-29^th, 2015

Gilbert Verbeken (Queen Astrid) gave a talk entitled "European Implementation of Bacteriophage Therapy: Impact of Medicinal Product Legislation on Tailored Hospital Care" during the Bacteriophages 2015 event, held in London (UK) in January. 

  here

Montesanto' castle

Old letter box ( year 1632)

Wiew of Sellano' Castle from Montesanto' Castle

News from AmpliPhi

A world first: Pherecydes Pharma launches multicenter clinical study of phage therapy in serious burn victims

Pay attention: read!

Bacteriophage Therapy: An Alternative Strategy to Combat Drug Resistance